Results 41 to 50 of about 9,498 (160)

A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose

Gut and Liver, 2020
Background/Aims: Sofosbuvir (SOF)-based therapy has been used in Korean patients with chronic hepatitis C virus (HCV) infection since January 2016. This study aimed to investigate the real-life effectiveness and safety of SOF-based therapy in genotype 2 ...
Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong   +7 more
doaj   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
Neglected tropical diseases (NTDs) remain a major global health challenge, particularly in low‐ and middle‐income countries. Kinetoplastid parasites causing Chagas disease, leishmaniasis, and African trypanosomiasis rely on host purine salvage pathways, making nucleoside analogues attractive therapeutic candidates.
Silvester Lowe, Vishal Satikuvar, Tanjia M. Syeda, Monica Cal, Pascal Mäser, Marcel Kaiser, Hachemi Kadri   +6 more
wiley   +1 more source

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients

Canadian Journal of Gastroenterology and Hepatology, 2016
Background and Aim. This is an open label prospective cohort study conducted at a tertiary care hospital. The primary endpoint is SVR12 in patients treated with sofosbuvir-based therapy in post-liver transplant patients with genotype 4 HCV recurrence ...
A. Ajlan, A. Al-Jedai, H. Elsiesy, D. Alkortas, W. Al-Hamoudi, R. Alarieh, M. Al-Sebayel, D. Broering, F. Aba Alkhail   +8 more
doaj   +1 more source

A New Era for Using Natural Pigments: The Case of the C50 Carotenoid Called Bacterioruberin

Biotechnology and Applied Biochemistry, Volume 73, Issue 2, Page 913-926, April 2026.
ABSTRACT Haloarchaea are extremophilic microorganisms belonging to the Archaea domain that require high salt concentrations to live, thus inhabiting ecosystems like salty ponds, salty marshes, or extremely salty lagoons. They are more abundant and widely distributed worldwide than initially expected.
Micaela Giani, Elena Valdés, José María Miralles‐Robledillo, Guillermo Martínez, Carmen Pire, Rosa María Martínez‐Espinosa   +5 more
wiley   +1 more source

A Case of Obstructive Jaundice due to Bile Duct Tumor Thrombus of Hepatocellular Carcinoma Diagnosed by Peroral Cholangioscopy

DEN Open, Volume 6, Issue 1, April 2026.
Abstract While hepatocellular carcinoma (HCC) often invades the portal or hepatic vein to form tumor thrombus, tumor thrombus in the bile duct is rare. In such cases, differentiation from intrahepatic cholangiocarcinoma is difficult, and the tumor often appears as a smooth, yellowish‐white, polypoid mass within the bile duct lumen.
Keisuke Kinoshita, Mizuki Endo, Tomoko Tokumaru, Tomoko Saito, Takuro Uchida, Masao Iwao, Mie Arakawa, Kazuhisa Okamoto, Masaaki Kodama, Kazunari Murakami   +9 more
wiley   +1 more source

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Biology, 2017
The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2.
Tatsuo Kanda, Masato Nakamura, Shin Yasui, Yuki Haga, Akinobu Tawada, Eiichiro Suzuki, Yoshihiko Ooka, Koji Takahashi, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Makoto Arai, Fumio Imazeki, Osamu Yokosuka   +13 more
doaj   +1 more source

Sofosbuvir and daclatasvir [PDF]

British Journal of Clinical Pharmacology, 2016
Chronic hepatitis C infection is a major cause of chronic liver disease, cirrhosis and liver cancer as well as an important indication for liver transplantation. Sofosbuvir (Sovaldi®) 1 and daclatasvir (Daklinza®) 2 are new direct acting antivirals (DAAs) with a favourable safety and tolerability profile, which have significantly changed treatment for ...
Marleen H. M. Hessel, Adam F. Cohen, Robert Rissmann   +2 more
openaire   +2 more sources